Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPAVASC: Dapagliflozin in Chronic Kidney Disease
NCT04930549Phase 2Completed
- Sponsor
- Rouen University Hospital
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Dapagliflozin 10 mg with Placebo (2 arms). Primary endpoint: Change from baseline of brachial artery endothelial function using echography at 12 weeks. Started Oct 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04930549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930549.